NHI covers additional indications of Remicade
Published: 2013-04-05 06:56:00
Updated: 2013-04-05 06:56:00
Janssen Korea said Wednesday that the additional indications of its TNF-alpha inhibitor Remicade, which was approved by the Korea Food and Drug Administration in 2000, has been further covered by national health insurance from April 1.
Under the recently revised health insurance scheme, Remic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
